Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
FDA establishment 3015212514, Minneapolis, Minnesota, United States. Part of Jon B. Cole, MD's FDA records. Every inspection FDA has posted for the site, with its outcome and cited regulations.
Inspections: 1
Official action indicated: 1
Form 483s posted: 1
Warning letters: 1
Inspections by fiscal year
FY2018 to FY2027 to date; 1 classified OAI
How to read this
A hatched bar is a year that is not over, so its count covers only part of the year.
20182018Inspections0
120192019Inspections1vs 2018+1
20202020Inspections0vs 2019−1
20212021Inspections0vs 2020+0
20222022Inspections0vs 2021+0
20232023Inspections0vs 2022+0
20242024Inspections0vs 2023+0
20252025Inspections0vs 2024+0
20262026Inspections0vs 2025+0
20272027 to dateInspections0
Most Cited at This Site
Inspections citing each reference
21 CFR 50.20: Consent not obtained, exceptions do not apply121 CFR 50.20: Consent not obtained, exceptions do not applyValue1
21 CFR 312.20(a): Failure to submit an IND121 CFR 312.20(a): Failure to submit an INDValue1
21 CFR 312.66: Changes in research121 CFR 312.66: Changes in researchValue1
21 CFR 50.20. Consent not obtained, exceptions do not apply Legally effective informed consent was not obtained from a subject or the subject's legally authorized representative, and the situation did not meet the criteria in 21 CFR 50.23 - 50.24 for exception.
21 CFR 312.20(a). Failure to submit an IND The sponsor failed to submit an IND to the FDA prior to conducting a clinical investigation with an investigational new drug.
21 CFR 312.66. Changes in research Not all changes in research activity were approved by an Institutional Review Board prior to implementation.
21 CFR 312.62(a). Accountability records Investigational drug disposition records are not adequate with respect to dates, quantity and use by subjects.
21 CFR 312.50. General responsibilities of sponsors Failure to ensure proper monitoring of the study.
21 CFR 312.60. FD-1572, protocol compliance An investigation was not conducted in accordance with the investigational plan.
Official Action Indicated (OAI)
Form 483 observations
What FDA investigators wrote up at the end of an inspection, from the 483s FDA posted; newest first
The sponsor failed to submit an IND to the FDA prior to conducting a clinical investigation with an investigational new drug.
Legally effective informed consent was not obtained from a subject or the subject's legally authorized representative, and the situation did not meet the criteria in 21 CFR 50.23 - 50.24 for exception.
An investigation was not conducted in accordance with the investigational plan.
Failure to ensure proper monitoring of the study.
Investigational drug disposition records are not adequate with respect to dates, quantity and use by subjects.
Not all changes in research activity were approved by an Institutional Review Board prior to implementation.
Warning letters
Letters naming this establishment; each opens the letter
An FEI (FDA Establishment Identifier) names one physical site. Inspections, outcomes and citations come from FDA's Data Dashboard; FDA posts citations only for some inspections. Recalls come from FDA's enforcement reports (iRES), one row per recall even when it covers many lots. A contract site can make products for many companies, so the company shown is the one FDA lists as the site's firm. Form 483 observations are read by Arca from the 483s FDA posts in its FOIA reading room, most of them scans: the first sentence of each observation, with redactions as FDA made them. FDA posts 483s for a minority of inspections.FDA Data Dashboard, warning letters and enforcement reports